Hep C Discussion Forum

Members Login
Username 
 
Password 
    Remember Me  
Chatbox
Please log in to join the chat!
Post Info TOPIC: ViralEd Independent Review of the 49th Annual EASL


Guru

Status: Offline
Posts: 3398
Date:
RE: ViralEd Independent Review of the 49th Annual EASL
Permalink  
 


Hi Wayne,

Good theoretical discussion where price and drug availability are ignored.

It's rather disappointing that how to diagnose cirrhosis is glossed over, when so much of the discussion focuses on the special needs of cirrhotics. Geno 2 and 3 were virtually ignored.

The question of Ribavirin use remains up in the air, and the Geno 1a and 1b differences confused me.

These discussions are worthwhile, but of limited value before FDA approvals and pricing announcements.

Nothing I heard changes my opinion that Geno 1 non-cirrhotics will have ~100% SVR with 12 weeks of Sovaldi/ Ledipasvir, and cirrhotics ideally should have 24 weeks for the same result.

It's good to hear that Sovaldi can be 're-used' for prior Sovaldi failures. Cheers.



__________________

Geno 1b, IL28B CT,  x3 prior relapser,  ex-cirrhotic, 75 yo, did 48 weeks with Victrelis/Peg./Riba.  VL 1.28m at start, UNDET. at 8 ,12 ,16 ,24 ,30  and 48 weeks.  EOT 15 Feb 2013 , UNDET. at EOT + 28 weeks. SVR!  Still Undet. at EOT +5 years

Malcolm

Tig


Admin

Status: Offline
Posts: 9270
Date:
Permalink  
 

Wayne,

There's a rule against posting this kind of information at midnight!  Just kidding!! If I get started on these things late at night, I end up watching them through the end. This one will have to wait til tomorrow! I do appreciate you posting this, looks like it will be a very worthwhile presentation, thank you.

Tig



__________________

Tig

67yo GT1A - 5 Mil - A2/F3 - (1996) Intron A - Non Responder, (2013) Peg/Riba/Vic SOT:05/23/13 EOT:12/04/13 SVR 9+ years!

Hep C FAQ   Lab Ref. Ranges  HCV Resistance

Signature Line Set Up/Abbreviations   Payment Assistance

 



Senior Member

Status: Offline
Posts: 380
Date:
Permalink  
 

Lengthy (90 min) but informative eSymposium discussing key data presented at the recently concluded EASL in London. Email address required to view. Topics include various study data (Pearl, Sapphire, Ion, Cosmos and others), treatment of cirrhotics, whether to use riba or not, re-treatment after failure, co-infection and more. Actual discussion begins at 3:30 mark.

Independent Review of 49th EASL

 



__________________

66 y/o male - Geno 1b - F4 cirrhotic dx 2001 - 16 wk treatment w/ Sovaldi/Olysio/Riba - Und @ EOT+24 SVR

 

Page 1 of 1  sorted by
 
Quick Reply

Please log in to post quick replies.

Legal Disclaimer:

THIS FORUM, IT'S OWNERS, ADMINISTRATORS, MODERATORS AND MEMBERS DO NOT AT ANY TIME GIVE MEDICAL ADVICE AND IN ALL CASES REFER ANYONE HERE TO SEEK APPROPRIATE MEDICAL ADVICE FROM THEIR DOCTOR.